Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.42 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197157 | 0.71 | CDK2 (0.47) | MAPKAPK2CDK2CHEK2CDK1CSNK1D | |
| SCHEMBL3203580 | 0.68 | MAPKAPK2 (0.49) | MAPKAPK2CDK2EGFRKDRAPP | |
| SCHEMBL5489325 | 0.62 | CDK2 (0.38) | CDK2 | |
| SCHEMBL1916553 | 0.61 | MAPK1 (0.46) | EGFRKDRAPPGRM4STK17A | |
| SCHEMBL12813342 | 0.57 | STK17A (0.57) | EGFRKDRAPPRAPGEF4GRM4 | |
| SCHEMBL656032 | 0.57 | SYK (0.72) | CDK2CDK1CSNK1DCDK5KDR | |
| SCHEMBL14871792 | 0.57 | MAPKAPK2 (0.47) | MAPKAPK2CDK2EGFRKDRGRM4 | |
| SCHEMBL9494328 | 0.57 | MEN1 (0.52) | RAPGEF4 | |
| SCHEMBL1392126 | 0.56 | APP (0.77) | APPRAPGEF4GRM4STK17A | |
| SCHEMBL6644848 | 0.56 | EGFR (0.48) | EGFRGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1780212-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | MAP3K1, MAP3K5, MAP3K15 | MAPKAPK2 35/4885CDK2 50/4885CHEK2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.